300) Canavan disease (CD) is a progressive, fatal neuro |
301) s been suggested to be involved in celiac disease (CD) pathogenesis by mediating int |
302) Chronic obstructive pulmonary disease (COPD) is the third leading cause |
303) iduals with chronic obstructive pulmonary disease (COPD). |
304) e responses involved in graft-versus-host disease (GVHD) and graft-versus-leukemia e |
305) d by the development of graft-versus-host disease (GVHD). |
306) predisposing factor in inflammatory bowel disease (IBD) and colitis-associated cance |
307) mplications, including inflammatory bowel diseases (IBD) and celiac disease, which w |
308) Non-alcoholic fatty liver disease (NAFLD) and its more severe form n |
309) style have made non-alcoholic fatty liver disease (NAFLD) one of the fastest growing |
310) patients affected by stroke, Parkinson's disease (PD), and multiple sclerosis (MS). |
311) tor and non-motor symptoms in Parkinson's disease (PD), there is limited evidence on |
312) s mellitus (type 1 and 2), chronic kidney disease (including dialysis), and chronic |
313) ng infective endocarditis, coronary heart disease (including myocardial infarction), |
314) ntrols were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dat |
315) We addressed this in 310 Alzheimer's Disease Neuroimaging Initiative (ADNI) par |
316) whereas relatively little is known about disease associations of SHANK1. |
317) Nicotine shows the most direct disease associations of these chemicals, f |
318) hip or sacroiliac joint affection of the disease but to other causes like pre-eclam |
319) , who are at presumed risk of more severe disease but who may also have decreased de |
320) nable them to increase control over their disease by better understanding and partic |
321) CR in patients with STEMI and multivessel disease by performing an updated network m |
322) ioidosis is a potentially fatal bacterial disease caused by Burkholderia pseudomalle |
323) Psittacosis is a zoonotic infectious disease caused by the transmission of Chla |
324) design, selection of study participants, disease classification, choice of control |
325) design, selection of study participants, disease classification, control choice, as |
326) an exposure variable and cerebrovascular disease, confirmed through assessment of v |
327) n social disadvantage and cerebrovascular disease, confirmed through assessment of v |
328) rches will need in terms of treatment and disease control. |
329) , cholera epidemics continue to challenge disease control. |
330) Disease definitions and thresholds varied |
331) ies measuring enteric disease, 8 provided disease definitions (n = 8/13, 61.2%); how |
332) ew era in translational modeling of human disease for research and preclinical devel |
|